Edition:
United Kingdom

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

8.28USD
12 Dec 2018
Change (% chg)

-- (--)
Prev Close
$8.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
209,040
52-wk High
$22.00
52-wk Low
$6.94

Latest Key Developments (Source: Significant Developments)

Abeona Therapeutics Says João Siffert Will Not Serve On Board During His Tenure As Interim CEO
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS INC - JOÃO SIFFERT WILL NOT SERVE ON BOARD OF DIRECTORS DURING HIS TENURE AS INTERIM CHIEF EXECUTIVE OFFICER - SEC FILING.ABEONA THERAPEUTICS - ON NOV 29, FRANK CARSTEN THIEL, CO ENTERED SEPARATION AGREEMENT.ABEONA THERAPEUTICS - SEPARATION AGREEMENT PROVIDING FRANK CARSTEN THIEL WILL NOT OTHERWISE BE ELIGIBLE FOR ANY ANNUAL BONUS OR SEVERANCE AMOUNT.  Full Article

Abeona Therapeutics Announces CEO Transition
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS ANNOUNCES CEO TRANSITION.ABEONA THERAPEUTICS INC - ANNOUNCED IMMEDIATE TERMINATION OF ITS CHIEF EXECUTIVE OFFICER, CARSTEN THIEL.ABEONA THERAPEUTICS INC - HAS APPOINTED JOÃO SIFFERT, AS INTERIM CHIEF EXECUTIVE OFFICER.ABEONA THERAPEUTICS INC - TERMINATION OF CEO "DUE TO PERSONAL MISCONDUCT THAT VIOLATED COMPANY'S CODE OF BUSINESS CONDUCT AND ETHICS".ABEONA THERAPEUTICS - THIEL'S TERMINATION FOLLOWS INVESTIGATION BY BOARD, EXTERNAL COUNSEL INTO ALLEGATIONS OF MISCONDUCT TOWARDS COLLEAGUES.ABEONA THERAPEUTICS INC - BOARD HAS FORMED A SEARCH COMMITTEE TO IDENTIFY A PERMANENT SUCCESSOR, WITH ASSISTANCE OF A EXECUTIVE SEARCH FIRM.  Full Article

Abeona Therapeutics Q3 Loss Per Share $0.34
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q3 LOSS PER SHARE $0.34.Q3 REVENUE $1.7 MILLION VERSUS $219,000.Q3 REVENUE VIEW $393,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.26 -- THOMSON REUTERS I/B/E/S.  Full Article

Abeona Therapeutics Q3 Loss Per Share $0.34
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q3 LOSS PER SHARE $0.34.Q3 REVENUE $1.7 MILLION VERSUS $219,000.Q3 REVENUE VIEW $393,000 -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $-0.26 -- THOMSON REUTERS I/B/E/S.  Full Article

Abeona Therapeutics May Offer And Sell Common Shares Of Up To $150 Mln Through Jefferies
Friday, 17 Aug 2018 

Aug 17 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS - MAY OFFER AND SELL COMMON SHARES OF UP TO $150 MILLION THROUGH JEFFERIES LLC.  Full Article

Abeona Therapeutics Q2 Loss Per Share $0.25
Thursday, 9 Aug 2018 

Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q2 LOSS PER SHARE $0.25.Q2 REVENUE $819,000 VERSUS $217,000.Q2 REVENUE VIEW $1.1 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2018 WERE $120 MILLION.  Full Article

Abeona Therapeutics Q2 Loss Per Share $0.25
Thursday, 9 Aug 2018 

Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q2 LOSS PER SHARE $0.25.Q2 REVENUE $819,000 VERSUS $217,000.Q2 REVENUE VIEW $1.1 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.  Full Article

Abeona Therapeutics Provides Clinical Update On MPS IIIA Gene Therapy Trial
Friday, 18 May 2018 

May 18 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS PROVIDES CLINICAL UPDATE ON MPS IIIA GENE THERAPY TRIAL AT THE 21ST ANNUAL ASGCT MEETING.ABEONA THERAPEUTICS- ABO-102 18-MONTH EFFICACY & SAFETY DATA CONTINUE TO DEMONSTRATE TIME- & DOSE-DEPENDENT REDUCTIONS IN UNDERLYING DISEASE PATHOLOGY.ABEONA THERAPEUTICS- RESULTS FROM PHASE 1/2 CLINICAL TRIAL FOR ABO-102 SHOW DURABLE BIOPHYSICAL REDUCTIONS OF DISEASE BURDEN.ABEONA THERAPEUTICS INC - ABO-102 IS WELL-TOLERATED IN ALL SUBJECTS TO DATE, WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS REPORTED.  Full Article

Abeona Therapeutics Posts Q1 Loss Of $0.18 Per Share
Friday, 11 May 2018 

May 11 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.Q1 LOSS PER SHARE $0.18.Q1 REVENUE $2.6 MILLION VERSUS $186,000.Q1 REVENUE VIEW $228,000 -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018 WERE $132 MILLION, COMPARED TO $137.8 MILLION AS OF DECEMBER 31, 2017.  Full Article

Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia
Monday, 23 Apr 2018 

April 23 (Reuters) - Abeona Therapeutics Inc ::ABEONA ANNOUNCES FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE THERAPY IN MPS IIIA.ABEONA THERAPEUTICS INC - COMPANY CONTINUES TO ENGAGE FDA ON ITS ONGOING PHASE 1/2 TRIAL.ABEONA - FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION TO ABO-102, CO'S GENE THERAPY FOR TREATMENT OF SANFILIPPO SYNDROME TYPE A.  Full Article